ER 172594-06 hydrobromide
| Code | Size | Price |
|---|
| SYN-3002-M100 | 100 mg | Enquire |
Quantity:
| SYN-3002-M050 | 50 mg | Enquire |
Quantity:
| SYN-3002-M001 | 1 mg | £238.00 |
Quantity:
| SYN-3002-M005 | 5 mg | £549.00 |
Quantity:
| SYN-3002-M010 | 10 mg | £848.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Atopaxar hydrobromide; ER-172594-06; E5555
Appearance:
Solid.
CAS:
474550-69-1
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H302, H317, H335
InChi:
InChI=1S/C29H38FN3O5.BrH/c1-7-37-23-15-19-16-33(28(31)24(19)25(30)27(23)38-8-2)17-22(34)18-13-20(29(3,4)5)26(35-6)21(14-18)32-9-11-36-12-10-32;/h13-15,31H,7-12,16-17H2,1-6H3;1H
InChiKey:
UNMBLVOFOAGGCG-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 474550-69-1. Formula: C29H39BrFN3O5 . HBr. MW: 608.5 . 80.9. E5555 shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031µM, respectively.
Molecular Formula:
C29H39BrFN3O5 . HBr
Molecular Weight:
608.5 . 80.9
Package Type:
Plastic Vial
Precautions:
P261, P264, P301, P312
Product Description:
E5555 shows potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC values of 0.064 and 0.031µM, respectively.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease: V.L. Serebruany, et al.; Thromb. Haemost. 102, 111 (2009) | Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease: S. Goto, et al.; Eur. Heart J. 31, 2601 (2010) | The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs: M. Kogushi, et al.; Eur. J. Pharmacol. 657, 131 (2011)
Related Products
| Product Name | Product Code | Supplier | Piperlongumine | AG-CN2-0024 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Forskolin | AG-CN2-0089 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Neoxaline | AG-CN2-0154 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cytochalasin B | AG-CN2-0504 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| YM-254890 | AG-CN2-0509 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BAY 11-7082 | AG-CR1-0013 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SIN-1 chloride | AG-CR1-0027 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sirtinol | AG-CR1-0055 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||